相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach et al.
Lancet Haematology (2020)
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
R. Garcia-Sanz et al.
ANNALS OF ONCOLOGY (2019)
Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy ( ICE) before Autologous Transplantation. Final Analysis of Phase II Study
Aspasia Stamatoullas et al.
BLOOD (2019)
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study
Anton Hagenbeek et al.
HAEMATOLOGICA (2019)
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce et al.
BLOOD (2018)
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
David J. Straus et al.
BLOOD (2018)
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD (2018)
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
A. F. Herrera et al.
ANNALS OF ONCOLOGY (2018)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
Alison J. Moskowitz et al.
BLOOD (2017)
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
Bruce D. Cheson et al.
BLOOD (2016)
Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses
Anthony Cao et al.
CANCER RESEARCH (2016)
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study
Armando Santoro et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)
Catherine S. Diefenbach et al.
BLOOD (2016)
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
Robert Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Brentuximab vedotin-mediated immunogenic cell death
Shyra J. Gardai et al.
CANCER RESEARCH (2015)
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Alison J. Moskowitz et al.
LANCET ONCOLOGY (2015)
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma
John Radford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Ajay K. Gopal et al.
BLOOD (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H. Moskowitz et al.
BLOOD (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
N. L. Bartlett et al.
ANNALS OF ONCOLOGY (2007)
Ifosfamide, gemcitabine, and vinorelbine: a now induction regimen for refractory and relapsed Hodgkin's lymphoma
Armando Santoro et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Time-intensified dexamethasone/cisplatin/cytarabine:: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease
A Josting et al.
ANNALS OF ONCOLOGY (2002)